Mergers & Acquisitions ·
Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash, valuing the deal at $1.65 billion
PCRXPacira BioSciences, Inc.
Viatris Inc. has entered into a definitive Agreement and Plan of Merger to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion. The transaction involves a two-step process: Viatris will first commence a cash tender offer for at least 50% plus one share of Pacira’s common stock, followed by a second-step merger to acquire any remaining shares. Both boards unanimously approved the deal and recommend that Pacira shareholders tender their shares. The acquisition is subject to customary closing conditions, including regulatory approval under the Hart-Scott-Rodino Act and the tender of a majority of outstanding shares. Viatris expects the transaction to close by the end of 2026 and anticipates it will be immediately accretive to its financial guidance metrics. Pacira BioSciences, Inc. develops and commercializes innovative non-opioid pain therapies.